LIDDS Share Price Performance
SEK 0.067
-0.08 (-53.15%)
Price SEK 0.067
Share PriceSEK 0.067
LIDDS Community Narratives
There are no narratives available yet.
Recent LIDDS News & Updates
No updates
LIDDS AB (publ) Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 28, 2025
- Earnings per share (EPS)
- -0.053
- Gross Margin
- -46,166.67%
- Net Profit Margin
- -80,488.89%
- Debt/Equity Ratio
- 0%
LIDDS AB (publ) Competitors
About LIDDS
- Founded
- 1999
- Employees
- 1
- CEO
- WebsiteView website
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemotherapy medication that is approved for various oncological condition, such as breast cancer, head and neck cancer, and prostate cancer; and NOV202, which is in clinical Phase Ib/IIa study to treat refractory cancer. The company also develops Liproca Depot, a NanoZolid-formulated 2-hydroxyltutamide (2-HOF), which is an anti-androgen drug for treating prostate cancer patients before radical treatments. It also has a research and development agreement with Johnson & Johnson Enterprise Innovation Inc. to develop oncology products based on the NanoZolid technology for a non-disclosed indication. The company was incorporated in 1999 and is based in Stockholm, Sweden.
Swedish Market Performance
- 7 Days: 0.6%
- 3 Months: 3.8%
- 1 Year: 2.5%
- Year to Date: 0.7%
Over the last 7 days, the market has dropped 1.5%, driven by a decline of 2.3% in the Industrials sector. Although the market performance has been flat over the past year. Earnings are forecast to grow by 17% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading